Program
Etoposide
Also written as “etoposide”, “Etoposide (dose level 1)” and “Etoposide (dose level 2)”.
Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Lymphoma, Large B-Cell, Diffuse · Lung Neoplasms · Ovarian Neoplasms, led by 20 companies.
Drug pageEtoposide: every studyMany companies study it; this page follows only the 28 they lead. All 598 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 41 open or running | phase 3since Dec 3, 2020 | Mar 12, 2018 | none ahead |
| Hoffmann-La Rocheits history only | 40 open or running | phase 3since Jul 19, 2019 | Oct 20, 2008 | none ahead |
| Bristol-Myers Squibbits history only | 20 open or running | phase 2since Jan 7, 2021 | Feb 20, 2019 | none ahead |
| Jiangsu HengRui Medicineits history only | 20 open or running | phase 3since Jun 24, 2019 | Jun 24, 2019 | none ahead |
| Amgenits history only | 10 open or running | phase 2since Nov 6, 2013 | Nov 6, 2013 | none ahead |
| BeOne Medicinesits history only | 10 open or running | phase 2since Feb 8, 2018 | Feb 8, 2018 | none ahead |
| BioNTechits history only | 11 open or running | phase 2since Jun 3, 2024 | Jun 3, 2024 | Jun 2027phase 2 · NCT06449209 |
| Boehringer Ingelheimits history only | 11 open or running | phase 3since Mar 4, 2026 | Mar 4, 2026 | Sep 9, 2028phase 3 · NCT07472517 |
| Eli Lillyits history only | 10 open or running | phase 2since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| EpicentRxits history only | 10 open or running | phase 2since Jun 29, 2015 | Jun 29, 2015 | none ahead |
| Gilead Sciencesits history only | 10 open or running | phase 1since Nov 17, 2017 | Nov 17, 2017 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 3since Aug 14, 2002 | Aug 14, 2002 | none ahead |
| Lederle Laboratoriesits history only | 10 open or running | phase 2since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Lee's Pharmaceuticalits history only | 10 open or running | phase 1since Apr 13, 2020 | Apr 13, 2020 | none ahead |
| Newsoara HYK Biopharmaceutical (Shanghai)its history only | 11 open or running | phase 2since Jul 2, 2025 | Jul 2, 2025 | Dec 2026phase 2 · NCT07136285 |
| Otsukaits history only | 10 open or running | phase 2since Jul 28, 2009 | Jul 28, 2009 | none ahead |
| Pfizerits history only | 10 open or running | phase 3since Sep 1, 2005 | Sep 1, 2005 | none ahead |
| Sanofiits history only | 10 open or running | phase 2since Apr 18, 2006 | Apr 18, 2006 | none ahead |
| Swami Rama Cancer Hospital and Research Instituteits history only | 10 open or running | phase 3since Sep 10, 2013 | Sep 10, 2013 | none ahead |
| Texas Oncology Cancer Centerits history only | 10 open or running | phase 2since Nov 18, 2011 | Nov 18, 2011 | none ahead |
Also a collaborator on its studies: Genelux.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 14 earlier studies, Nov 2, 1999 to Mar 12, 2018.
- Dec 9, 2016Named etoposideINNProposed as its International Nonproprietary Name in WHO's List 116
- Feb 20, 2019Bristol-Myers Squibb’s first study: phase 1 study in Small Cell Lung CarcinomaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT03850067 · 90 enrolled · France, Italy, Spain
- Apr 29, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT03944772 · 247 enrolled · United States, Denmark, Italy and more
- Jun 24, 2019Jiangsu HengRui Medicine’s first study: phase 3 study in Ovarian NeoplasmsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT04000295 · 280 enrolled · China
- Jul 19, 2019Phase 3 study in Small Cell Lung CarcinomaHoffmann-La Roche · NCT04028050 · 155 enrolled · Italy
- Apr 13, 2020Lee's Pharmaceutical’s first study: phase 1 study in Extensive Stage Small Cell Lung CancerNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT04346914 · 20 enrolled · China
- May 6, 2020Phase 2 study in Ovarian NeoplasmsJiangsu HengRui Medicine · NCT04383977 · 54 enrolled
- Nov 4, 2020Phase 2 study in Small Cell Lung CarcinomaHoffmann-La Roche · NCT04622228 · 56 enrolled · China
- Dec 3, 2020Phase 3 study in Small Cell Lung Carcinoma Extensive DiseaseAstraZeneca · NCT04712903 · 101 enrolled · Spain
- Jan 7, 2021Phase 2 study in Small Cell Lung CarcinomaBristol-Myers Squibb · NCT04702880 · 135 enrolled · United States, Australia, Belgium and more
- Feb 25, 2021Phase 3 study in Small Cell Lung CarcinomaAstraZeneca · NCT04774380 · 152 enrolled · Bulgaria, Canada, Czechia and more
- May 3, 2022Phase 1 study in Lymphoma, Large B-Cell, DiffuseHoffmann-La Roche · NCT05364424 · 43 enrolled · United States
- Jun 3, 2024BioNTech’s first study: phase 2 study in Small Cell Lung CarcinomaNew to BioNTechBioNTech · NCT06449209 · 110 enrolled · United States, Australia, South Korea and more
- Jul 2, 2025Newsoara HYK Biopharmaceutical (Shanghai)’s first study: phase 2 study in SCLC, Extensive StageNew to Newsoara HYK Biopharmaceutical (Shanghai)Newsoara HYK Biopharmaceutical (Shanghai) · NCT07136285 · 27 planned · China
- Mar 4, 2026Boehringer Ingelheim’s first study: phase 3 study in Small Cell Lung CarcinomaNew to Boehringer IngelheimBoehringer Ingelheim · NCT07472517 · 670 planned · United States, Argentina, Australia and more
Ahead
- Dec 2026Primary completion: phase 2 study in SCLC, Extensive StageNewsoara HYK Biopharmaceutical (Shanghai) · NCT07136285
- Jun 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaBioNTech · NCT06449209
- Sep 9, 2028Primary completion: phase 3 study in Small Cell Lung CarcinomaBoehringer Ingelheim · NCT07472517
TargetBeta
“DNA topoisomerase II inhibitor”ChEMBL 37, by rule
Studies
All 28 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07472517Small Cell Lung Carcinoma · United States, Argentina, Australia and more | 3 | Recruiting | Boehringer Ingelheim | Sep 9, 2028 | 670 |
| NCT07136285SCLC, Extensive Stage · China | 2 | Recruiting | Newsoara HYK Biopharmaceutical (Shanghai) | Dec 2026 | 27 |
| NCT06449209Small Cell Lung Carcinoma · United States, Australia, South Korea and more | 2 | Active, not recruiting | BioNTech | Jun 2027 | 110 |
| NCT05364424Lymphoma, Large B-Cell, Diffuse · United States | 1 | Completed | Hoffmann-La Roche | Oct 15, 2025 | 43 |
| NCT04774380Small Cell Lung Carcinoma · Bulgaria, Canada, Czechia and more | 3 | Completed | AstraZeneca | Jun 12, 2023 | 152 |
| NCT04702880Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 2 | Completed | Bristol-Myers Squibb | May 22, 2025 | 135 |
| NCT04712903Small Cell Lung Carcinoma Extensive Disease · Spain | 3 | Completed | AstraZeneca | Jun 21, 2023 | 101 |
| NCT04622228Small Cell Lung Carcinoma · China | 2 | Completed | Hoffmann-La Roche | Jun 21, 2022 | 56 |
| NCT04383977Ovarian Neoplasms | 2 | UNKNOWN | Jiangsu HengRui Medicine | Dec 2020 | 54 |
| NCT04346914Extensive Stage Small Cell Lung Cancer · China | 1 | UNKNOWN | Lee's Pharmaceutical | Oct 30, 2022 | 20 |
| NCT04028050Small Cell Lung Carcinoma · Italy | 3 | Completed | Hoffmann-La Roche | Jul 13, 2023 | 155 |
| NCT04000295Ovarian Neoplasms · China | 3 | UNKNOWN | Jiangsu HengRui Medicine | Jan 2021 | 280 |
| NCT03944772Carcinoma, Non-Small-Cell Lung · United States, Denmark, Italy and more | 2 | Active, not recruiting | AstraZeneca | May 6, 2025 | 247 |
| NCT03850067Small Cell Lung Carcinoma · France, Italy, Spain | 1 | Completed | Bristol-Myers Squibb | Jul 16, 2024 | 90 |
| NCT03509012Squamous Cell Carcinoma of Head and Neck · United States, Japan, Korea, Republic of and more | 1 | Completed | AstraZeneca | Dec 31, 2020 | 105 |
| NCT03432598Lung Neoplasms · China | 2 | Completed | BeOne Medicines | Feb 25, 2019 | 54 |
| NCT03349346Lymphoma, Large B-Cell, Diffuse · France, Italy, Poland and more | 1 | Withdrawn | Gilead Sciences | Feb 2021 | 0 |
| NCT02489903Carcinoma, Small Cell · United States | 2 | Completed | EpicentRx | Dec 6, 2021 | 139 |
| NCT01987232Small Cell Lung Carcinoma · United States, Canada, Russian Federation | 2 | Completed | Amgen | Aug 2016 | 32 |
| NCT01947062Lung Neoplasms · India | 3 | UNKNOWN | Swami Rama Cancer Hospital and Research Institute | Jun 2014 | 60 |
| NCT01500161Leukemia, Myeloid, Acute · United States | 2 | Terminated | Texas Oncology Cancer Center | Nov 2013 | 1 |
| NCT00948090Lymphoma · United States, Canada | 2 | Completed | Otsuka | May 2013 | 207 |
| NCT00776698Non-Squamous Non-Small Cell Lung Cancer · Netherlands, United Kingdom | 1 | Completed | Hoffmann-La Roche | Feb 2010 | 1 |
| NCT00315705Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States | 2 | Completed | Sanofi | May 2010 | 50 |
| NCT00191139Carcinoma, Non-Small-Cell Lung · United States, Argentina, China and more | 2 | Completed | Eli Lilly | Nov 2008 | 64 |
| NCT00143455Small Cell Lung Carcinoma · Austria, Belgium, Czech Republic and more | 3 | Completed | Pfizer | Dec 2008 | 485 |
| NCT00043927Small Cell Lung Carcinoma · United States, Austria, Belgium and more | 3 | Completed | GlaxoSmithKline | Jan 2004 | 760 |
| NCT00002003Lymphoma, Non-Hodgkin · United States | 2 | Completed | Lederle Laboratories |
How it is read
Names in the registry
- “Etoposide”, 18 entries
- “etoposide”, 3 entries
- “Etoposide (dose level 1)”, 1 entry
- “Etoposide (dose level 2)”, 1 entry
- “recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 12 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Lymphoma, Large B-Cell, Diffuse, 2 studies
- Lung Neoplasms, 2 studies
- Ovarian Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.